EP1315499A4 - Compositions et methodes destinees au traitement des troubles anorectaux - Google Patents

Compositions et methodes destinees au traitement des troubles anorectaux

Info

Publication number
EP1315499A4
EP1315499A4 EP01957348A EP01957348A EP1315499A4 EP 1315499 A4 EP1315499 A4 EP 1315499A4 EP 01957348 A EP01957348 A EP 01957348A EP 01957348 A EP01957348 A EP 01957348A EP 1315499 A4 EP1315499 A4 EP 1315499A4
Authority
EP
European Patent Office
Prior art keywords
compositions
treatment
methods
anorectal disorders
anorectal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01957348A
Other languages
German (de)
English (en)
Other versions
EP1315499A1 (fr
Inventor
Thomas P Parks
Vivien Mak
Jung-Chung Lee
Charles Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Strakan International Ltd Great Britain
Original Assignee
Strakan International Ltd Great Britain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Strakan International Ltd Great Britain filed Critical Strakan International Ltd Great Britain
Publication of EP1315499A1 publication Critical patent/EP1315499A1/fr
Publication of EP1315499A4 publication Critical patent/EP1315499A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)
EP01957348A 2000-07-31 2001-07-30 Compositions et methodes destinees au traitement des troubles anorectaux Withdrawn EP1315499A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22226700P 2000-07-31 2000-07-31
US222267P 2000-07-31
PCT/US2001/023971 WO2002009714A1 (fr) 2000-07-31 2001-07-30 Compositions et methodes destinees au traitement des troubles anorectaux

Publications (2)

Publication Number Publication Date
EP1315499A1 EP1315499A1 (fr) 2003-06-04
EP1315499A4 true EP1315499A4 (fr) 2007-09-05

Family

ID=22831555

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01957348A Withdrawn EP1315499A4 (fr) 2000-07-31 2001-07-30 Compositions et methodes destinees au traitement des troubles anorectaux

Country Status (8)

Country Link
EP (1) EP1315499A4 (fr)
JP (1) JP2004516244A (fr)
KR (3) KR20100017750A (fr)
AU (1) AU2001279104A1 (fr)
CA (1) CA2417848A1 (fr)
IL (1) IL154202A0 (fr)
MX (1) MXPA03000931A (fr)
WO (1) WO2002009714A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020588D0 (en) * 2000-08-21 2000-10-11 Pfizer Ltd Treatment of wounds
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
KR101067443B1 (ko) 2009-06-23 2011-09-27 여오영 하이드록시클로로퀸을 함유하는 치핵 치료를 위한 국소투여용 주사제 조성물
CN102145004B (zh) * 2010-02-09 2012-03-21 鲁南制药集团股份有限公司 己酮可可碱在制备预防或治疗功能性便秘的药物中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043354A2 (fr) * 1998-02-27 1999-09-02 Synchroneuron, Llc Methode de traitement des etats douloureux de la region anale et compositions correspondantes
WO2000035434A2 (fr) * 1998-12-14 2000-06-22 Cellegy Pharmaceuticals, Inc. Compositions et techniques de traitement de troubles anorectaux

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595753A (en) 1995-04-14 1997-01-21 President And Fellows Of Harvard College Topical formulations and methods for treating hemorrhoidal pain and sphincter and smooth muscle spasm in the gastrointestinal tract

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043354A2 (fr) * 1998-02-27 1999-09-02 Synchroneuron, Llc Methode de traitement des etats douloureux de la region anale et compositions correspondantes
WO2000035434A2 (fr) * 1998-12-14 2000-06-22 Cellegy Pharmaceuticals, Inc. Compositions et techniques de traitement de troubles anorectaux

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0209714A1 *

Also Published As

Publication number Publication date
KR100863758B1 (ko) 2008-10-16
KR20030024826A (ko) 2003-03-26
CA2417848A1 (fr) 2002-02-07
EP1315499A1 (fr) 2003-06-04
WO2002009714A1 (fr) 2002-02-07
WO2002009714A9 (fr) 2003-03-06
JP2004516244A (ja) 2004-06-03
IL154202A0 (en) 2003-07-31
KR20100017750A (ko) 2010-02-16
AU2001279104A1 (en) 2002-02-13
KR20080068145A (ko) 2008-07-22
MXPA03000931A (es) 2004-08-12

Similar Documents

Publication Publication Date Title
PL348817A1 (en) Compositions and methods for the treatment of anorectal disorders
AU2001271973A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2001278852A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
GB0007193D0 (en) Treatment of movrmrnt disorders
AU6147401A (en) Compositions and methods for the treatment of cancer
AU2003213787A1 (en) Compositions and methods for the treatment of anorectal disorders
AU5714601A (en) Methods for prevention and treatment of gastrointestinal disorders
GB0010669D0 (en) Compositions for treatment of disorders of the oesophagus
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
ZA200301204B (en) Compositions and methods for the diagnosis and treatment of tumor
EP1335736A4 (fr) Compositions et methodes de diagnostic et de traitement de troubles cardio-vasculaires
HUP0302718A3 (en) Methods and compositions for the treatment of diseases of the eye
AU8678501A (en) Compositions and methods for the diagnosis and treatment of tumor
IL155433A0 (en) Treatment of t cell disorders
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
AU2002363935A1 (en) Composition and method for the treatment of anorectal disorders
HRP20030384A2 (en) Treatment of anxiety disorders
AU6137801A (en) Method and composition for the treatment of angiogenesis
CZ20011872A3 (cs) Isonipekotamidy pro léčbu onemocnění zprostředkovaných integriny
IL154202A0 (en) Pharmaceutical compositions for treating anorectal disorders
AUPQ872800A0 (en) Compositions and methods for treating cardiovascular disorders
EP1305017A4 (fr) Procedes et compositions pour la prevention et le traitement du syndrome x
EP1440165A4 (fr) Methodes et compositions destinees au traitement et au diagnostic de troubles lies a la proliferation cellulaire au moyen de 25943
EP1440166A4 (fr) Procedes et compositions destines a diagnostiquer et a traiter des troubles hematologiques au moyen de 2777
HK1038311A (en) Compositions and methods for the treatment of anorectal disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030214

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LEE, CHARLES

Inventor name: LEE, JUNG-CHUNG

Inventor name: MAK, VIVIEN

Inventor name: PARKS, THOMAS, P.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CELLEGY PHARMACEUTICALS, INC

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CELLEGY PHARMACEUTICALS, INC

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: STRAKAN INTERNATIONAL LIMITED

111Z Information provided on other rights and legal means of execution

Free format text: ATBECHCYDEDKESFIFRGBGRIEITLUMCNLPTSETR

Effective date: 20070517

A4 Supplementary search report drawn up and despatched

Effective date: 20070808

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20080114